Analyst Initiates Coverage on Cartesian Therapeutics with Buy Rating and Sets Price Target

Mar 4, 2024

On March 4, 2024, Mitchell Kapoor, an analyst at HC Wainwright & Co., initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with

CONNECT & FOLLOW